Plus Therapeutics (PSTV) Return on Capital Employed (2016 - 2025)
Plus Therapeutics (PSTV) has disclosed Return on Capital Employed for 15 consecutive years, with 15.05% as the latest value for Q3 2025.
- On a quarterly basis, Return on Capital Employed fell 1991.0% to 15.05% in Q3 2025 year-over-year; TTM through Sep 2025 was 15.05%, a 1991.0% decrease, with the full-year FY2024 number at 2.25%, up 418.0% from a year prior.
- Return on Capital Employed was 15.05% for Q3 2025 at Plus Therapeutics, down from 3.29% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 12.29% in Q1 2025 to a low of 15.05% in Q3 2025.
- A 5-year average of 1.14% and a median of 1.19% in 2022 define the central range for Return on Capital Employed.
- Peak YoY movement for Return on Capital Employed: soared 997bps in 2024, then crashed -1991bps in 2025.
- Plus Therapeutics' Return on Capital Employed stood at 0.81% in 2021, then tumbled by -109bps to 1.69% in 2022, then crashed by -390bps to 8.29% in 2023, then skyrocketed by 120bps to 1.68% in 2024, then tumbled by -996bps to 15.05% in 2025.
- Per Business Quant, the three most recent readings for PSTV's Return on Capital Employed are 15.05% (Q3 2025), 3.29% (Q2 2025), and 12.29% (Q1 2025).